Applications of genomics in NSCLC.
暂无分享,去创建一个
G. Altavilla | R. Rosell | M. Taron | M. Santarpia | O. Etxaniz | J. Sánchez | M. Cobo | T. Morán | D. Isla | S. Catot
[1] Mayumi Ono,et al. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.
[2] C. García-Girón,et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] C. Obasaju,et al. Updated report of a phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs. immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Felip,et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p) , 2005 .
[5] D. Gandara,et al. Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504) , 2005 .
[6] T. Chou,et al. Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[7] V. Georgoulias,et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Shepherd,et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[10] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. Milleron,et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[12] E. Lemarié,et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] S. Groshen,et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. , 2005, Journal of the American College of Surgeons.
[14] S. Toyooka,et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] E. Felip,et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. , 2004, Human molecular genetics.
[16] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[17] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[18] H. You,et al. Protect Cells from Platinum-Based Anticancer Agents Oncogenic HRas UpRegulates Expression of ERCC 1 to Updated , 2004 .
[19] E. Felip,et al. Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery , 2004, Clinical Cancer Research.
[20] G. Bepler,et al. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.
[21] R. Rosell,et al. Influence of genetic markers on survival in non-small cell lung cancer. , 2003, Drugs of today.
[22] P. Johnston,et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.
[23] R. Ramlau,et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. Felip,et al. Genetic testing for chemotherapy in non-small cell lung cancer. , 2003, Lung cancer.
[25] G. Bepler,et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. , 2003, Seminars in Oncology.
[26] M. Perry,et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Scagliotti,et al. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[28] G. Bepler,et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.
[29] R. Livingston,et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Fedier,et al. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. , 2003, International journal of oncology.
[31] C. Boland,et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells , 2003, British Journal of Cancer.
[32] Stephen B. Baylin,et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer , 2003, Nature.
[33] M. Selvakumaran,et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. , 2003, Cancer research.
[34] Y. Pommier,et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. , 2002, Cancer research.
[35] M. Spitz,et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. , 2002, Journal of the National Cancer Institute.
[36] D. Gandara,et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[38] S. Groshen,et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] I. Vlachonikolis,et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.
[41] T. Hickish,et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Johnson,et al. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.
[43] D. Murray,et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells , 2000, International journal of cancer.
[44] H. Bartelink,et al. DNA‐adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy , 2000, International journal of cancer.
[45] K. Gardner,et al. Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells* , 1998, The Journal of Biological Chemistry.
[46] E. Venkatraman,et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.
[47] M. Tsao,et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. , 1995, Cancer research.
[48] O. Brodin,et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .
[49] J. Yu,et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.
[50] J. Crowley,et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Schiller,et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] S. Groshen,et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.